Notably, in addition to AML, adrenocortical carcinoma and thyroid carcinoma demonstrate decreased MTF2 levels and concomitant elevated MDM2 expression (Figure 3B), suggesting that loss of MTF2 in adrenocortical carcinoma and thyroid carcinoma could impact disease progression and therapeutic response. This evidence concerns the gene MTF2 and thyroid gland carcinoma.